Quarterly report pursuant to Section 13 or 15(d)

Fair Value (Details)

v3.21.2
Fair Value (Details)
$ in Thousands
3 Months Ended 9 Months Ended
Oct. 04, 2019
USD ($)
Oct. 02, 2021
USD ($)
Sep. 26, 2020
USD ($)
Mar. 28, 2020
reporting_unit
Oct. 02, 2021
USD ($)
Sep. 26, 2020
USD ($)
reporting_unit
Dec. 31, 2020
USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis              
Selling, general and administrative expense   $ 21,729 $ 24,170   $ 66,829 $ 85,941  
Number of reporting units impaired | reporting_unit       4   4  
Right-of-use asset impairment   0 $ 0   0 $ 691  
Aerospace Segment              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis              
Impairment loss           86,300  
AeroSat              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis              
Right-of-use asset impairment           $ 700  
Diagnosys              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis              
Cash paid to acquire stock $ 7,000            
Fair value of contingent consideration 2,500 $ 0     0   $ 2,200
Potential additional earn-out $ 13,000            
Achievement period 3 years            
Earn-out achievement benchmark $ 72,000            
Selling, general and administrative expense         $ 2,200